Tissue and Functional Assessment of Myocardial Injury in Hodgkin Lymphoma (HL) Survivors

Active, not recruitingOBSERVATIONAL
Enrollment

133

Participants

Timeline

Start Date

April 30, 2014

Primary Completion Date

April 30, 2026

Study Completion Date

April 30, 2026

Conditions
Hodgkin Lymphoma Survivor
Interventions
OTHER

Clinical Assessment

HL treatment will be determined by review of available medical records as archived at MSKCC. Recorded variables will include: (1) RT - field, fractional and cumulative dose, and duration; (2) chemotherapy - regimen, planned interval, dose per cycle, and cumulative dosages. Patients will also be asked to complete the FACT-LYM questionnaire and the FACIT Fatigue questionnaire.

PROCEDURE

Stress cardiac MRI

Both imaging tests will be performed within a 30 day interval, with the two modalities interpreted by dedicated study investigators blinded to the results of the other modality.

PROCEDURE

Stress echocardiogram

Both imaging tests will be performed within a 30 day interval, with the two modalities interpreted by dedicated study investigators blinded to the results of the other modality.

Trial Locations (1)

10065

Memorial Sloan Kettering Cancer Center, New York

All Listed Sponsors
collaborator

Weill Medical College of Cornell University

OTHER

lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT02106611 - Tissue and Functional Assessment of Myocardial Injury in Hodgkin Lymphoma (HL) Survivors | Biotech Hunter | Biotech Hunter